8 Jun 2001 QLT Inc. and Kinetek Pharmaceuticals, Inc. announced they have entered into a long- term research, development and license agreement to develop compounds known as signal transduction inhibitors for the treatment of eye, immune system and kidney diseases.
Signal transduction focuses on defects in cellular functions in certain disease states.
First, proteins involved in cellular communications whose presence correlates with the onset of a wide range of diseases are identified and validated as targets. A series of drug candidates are then generated to selectively inhibit these targets. Kinetek has established a leadership position in this emerging field through the identification of proprietary targets and corresponding inhibitors. We believe that Kinetek's expertise in drug discovery and medicinal chemistry combined with QLT's proven track record in drug development and commercialization provides a strong foundation for a successful collaboration. This transaction further validates our technology platform and ability to discover compounds with significant commercial potential.